---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-047701"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T02:28:17.718381+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics reports FY2024 net loss of $56.6M; cash to Q3 2025; RT-114 preclinical data positive

## Summary
- FY2024 net loss of $56.6M vs $67.9M in 2023; cash and marketable securities $27.6M, expected to fund operations into Q3 2025.
- Preclinical data for RT-114 (GLP-1/GLP-2 dual agonist) shows 111% relative bioavailability vs subcutaneous, with bioequivalence and comparable weight loss.
- Preclinical data for semaglutide oral via RaniPill HC (RT-116) shows bioavailability, PK, and weight loss comparable to subcutaneous.
- Phase 1 study of RT-114 for obesity expected to initiate mid-2025; partnership with ProGen for co-development of RT-114.
- Impairment loss of $3.7M on construction-in-progress equipment; R&D expenses down $12.9M YoY due to workforce reduction.

## SEC filing metadata
- accession: 0000950170-25-047701
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017025047701/0000950170-25-047701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017025047701/rani-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-047701
- JSON: https://secwatch.observer/filing/0000950170-25-047701.json
- Plain text: https://secwatch.observer/filing/0000950170-25-047701.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.